BBC NEWS Americas Africa Europe Middle East South Asia Asia Pacific Arabic Spanish Russian Chinese Welsh
BBCi CATEGORIES   TV   RADIO   COMMUNICATE   WHERE I LIVE   INDEX    SEARCH 

BBC NEWS
 You are in:  Health
Front Page 
World 
UK 
UK Politics 
Business 
Sci/Tech 
Health 
Background Briefings 
Medical notes 
Education 
Entertainment 
Talking Point 
In Depth 
AudioVideo 


Commonwealth Games 2002

BBC Sport

BBC Weather

SERVICES 
Tuesday, 19 February, 2002, 07:53 GMT
HIV 'singled out for destruction'
HIV cells
The drug tackles weakened HIV-infected cells
HIV-infected immune cells could be specifically targeted by a drug originally tested as a cancer treatment.

Although tests are at an early stage, scientists are hopeful that this could destroy only the cells harbouring HIV, leaving the rest of the immune system unharmed.

Doctors are hoping to launch limited clinical trials in the US within the next few month.


Clearly, more work with Gd-Tex is necessary, but in our battle to stay one step ahead of the ever-mutating virus, different treatment options are vital

Mark Graver, Terrence Higgins Trust
HIV is so devastating because it takes over and kills a type of blood cell called a CD4+ helper T cells.

CD4+ helper T cells are crucial because they help coordinate the immune defences against foreign invaders such as bacteria.

Without them, HIV patients are vulnerable to a wide range of illnesses.

However, researchers from Stanford University Medical Center have been testing the drug, called motexafin gadolinium (Gd-Tex), on immune cells in the laboratory.

Kill the weakest

They found that, even in low doses, the drug appeared to selectively kill only the cells infected with HIV.

They believe that because the HIV infected cells are already weakened, and the attack from the drug simply "pushes it over the edge" - but spares non-infected cells because they are more resilient.

The lead author of the study, Omar Perez, said: "The first clue that Gd-Tex worked was that the CD4+ T cells were disappearing."

However, it is not yet clear whether the transfer from laboratory to live patient can be made successfully.

In particular, it may be harder to produce a precise level of Gd-Tex in the body than in a test tube.

Risks to patients

And doctors fear that the speedy breakdown of CD4+ T cells could release harmful toxins into the body.

However, the pharmaceutical company which makes Gd-Tex is hoping to begin clinical trials of the drug in HIV patients within the next few months.

A spokesman for the Terrence Higgins Trust said: "It is exciting & interesting that a range of different approaches to HIV treatments such as this one are being tried.

"Clearly, more work with Gd-Tex is necessary, but in our battle to stay one step ahead of the ever-mutating virus, different treatment options are vital."

See also:

31 Jan 02 | Health
HIV numbers to rise sharply
06 Jan 02 | Health
Gene offers HIV drug success
Internet links:


The BBC is not responsible for the content of external internet sites

Links to more Health stories are at the foot of the page.


E-mail this story to a friend

Links to more Health stories